Biomarker & Intervention Discovery

Neck Pain (Chronic)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

GRIN1 183IL6 173NGF 9PTGS2 299SCN9A 271TRPV1 160
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COMPOUND 53 [PMID: 33038794] activates Mechanistic
PAREGORIC ? unclear Mechanistic
STING AGONIST 2 activates Mechanistic
LATREPIRDINE ? unclear Mechanistic
CNS-5161 inhibits Mechanistic
MEMANTINE HYDROCHLORIDE ~ modulates Mechanistic
LANICEMINE inhibits Mechanistic
ULEVOSTINAG activates Mechanistic
ELIPRODIL ? unclear Mechanistic
NBQX ? unclear Mechanistic
RAPASTINEL ? unclear Mechanistic
DEXANABINOL ? unclear Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
HALOPERIDOL DECANOATE ? unclear Mechanistic
ORPHENADRINE ? unclear Mechanistic
GW468816 inhibits Mechanistic
ACAMPROSATE CALCIUM inhibits Mechanistic
AMANTADINE HYDROCHLORIDE inhibits Mechanistic
H-151 inhibits Mechanistic
D-SERINE ? unclear Mechanistic
AZD8108 inhibits Mechanistic
KETAMINE HYDROCHLORIDE ~ modulates Mechanistic
DELUCEMINE inhibits Mechanistic
EVT-101 inhibits Mechanistic
MSA-2 activates Mechanistic
ESKETAMINE HYDROCHLORIDE ? unclear Mechanistic
2'3'-CGAMP activates Mechanistic
COMPOUND 40 [PMID: 33470814] activates Mechanistic
PHILANTHOTOXIN 343 ? unclear Mechanistic
FELBAMATE inhibits Mechanistic
INDANTADOL inhibits Mechanistic
STING AGONIST 3 activates Mechanistic
ORPHENADRINE HYDROCHLORIDE inhibits Mechanistic
CYCLOSERINE ? unclear Mechanistic
RADIPRODIL inhibits Mechanistic
PERZINFOTEL inhibits Mechanistic
ESKETAMINE ~ modulates Mechanistic
ADU-S100 activates Mechanistic
RALFINAMIDE inhibits Mechanistic
SNX281 activates Mechanistic

Showing top 40 of 183 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MEDI-578 inhibits Mechanistic
CERE-110 ? unclear Mechanistic
FASINUMAB inhibits Mechanistic
TANEZUMAB inhibits Mechanistic
FRUNEVETMAB ~ modulates Mechanistic
FULRANUMAB inhibits Mechanistic
BEDINVETMAB ~ modulates Mechanistic
PG-110 inhibits Mechanistic
CHEMBL1397270 inhibits Mechanistic 1000.0 nM (IC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN inhibits Mechanistic 102.0 nM (IC50)
INDOMETHACIN SODIUM inhibits Mechanistic
DARBUFELONE ? unclear Mechanistic
MEFENAMIC ACID inhibits Mechanistic
MECLOFENAMATE SODIUM inhibits Mechanistic
DICLOFENAC SODIUM inhibits Mechanistic
CAPECITABINE ? unclear Mechanistic
PIRPROFEN inhibits Mechanistic
ESFLURBIPROFEN inhibits Mechanistic
SULFASALAZINE inhibits Mechanistic
BROMFENAC ? unclear Mechanistic
IBUPROFEN, SODIUM SALT inhibits Mechanistic
ALOXIPRIN inhibits Mechanistic
TENOXICAM ? unclear Mechanistic
FLURBIPROFEN inhibits Mechanistic
SALICYLIC ACID ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
DEXKETOPROFEN inhibits Mechanistic
ETORICOXIB inhibits Mechanistic
LUMIRACOXIB inhibits Mechanistic
SUPROFEN inhibits Mechanistic
NS-398 ? unclear Mechanistic
NABUMETONE inhibits Mechanistic
URSOLIC ACID ? unclear Mechanistic
IBUPROFEN LYSINE inhibits Mechanistic
ACECLOFENAC inhibits Mechanistic
IBUFENAC inhibits Mechanistic
BALSALAZIDE ? unclear Mechanistic
DIFLUNISAL inhibits Mechanistic
BALSALAZIDE DISODIUM inhibits Mechanistic
VACCINE ? unclear Mechanistic
KETOROLAC TROMETHAMINE inhibits Mechanistic
BENZYDAMINE HYDROCHLORIDE inhibits Mechanistic
TIAPROFENIC ACID ? unclear Mechanistic
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic
NAPROXCINOD inhibits Mechanistic
IGURATIMOD inhibits Mechanistic
ETODOLAC inhibits Mechanistic
DICLOFENAC ETALHYALURONATE SODIUM inhibits Mechanistic
ROFECOXIB inhibits Mechanistic 530.0 nM (IC50)

Showing top 40 of 299 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MERETHOXYLLINE PROCAINE inhibits Mechanistic
ETIDOCAINE HYDROCHLORIDE inhibits Mechanistic
FOSPHENYTOIN inhibits Mechanistic
VERATRIDINE activates Mechanistic
ORPHENADRINE CITRATE inhibits Mechanistic
PHENACEMIDE inhibits Mechanistic
LACOSAMIDE inhibits Mechanistic
VIXOTRIGINE inhibits Mechanistic
DSP-2230 inhibits Mechanistic
SAXITOXIN inhibits Mechanistic
ESLICARBAZEPINE ACETATE inhibits Mechanistic
SAFINAMIDE ? unclear Mechanistic
LIDOCAINE inhibits Mechanistic
RILUZOLE inhibits Mechanistic
ROPIVACAINE HYDROCHLORIDE inhibits Mechanistic
FUNAPIDE inhibits Mechanistic
DYCLONINE HYDROCHLORIDE inhibits Mechanistic
EVENAMIDE inhibits Mechanistic
PROPOFOL ? unclear Mechanistic
AM-6120 inhibits Mechanistic
RG7893 inhibits Mechanistic
RG6029 inhibits Mechanistic
QUINIDINE SULFATE inhibits Mechanistic
ZONISAMIDE inhibits Mechanistic
NERISPIRDINE inhibits Mechanistic
RALFINAMIDE inhibits Mechanistic
DS-1971A inhibits Mechanistic
HEXYLCAINE HYDROCHLORIDE inhibits Mechanistic
MEPIVACAINE HYDROCHLORIDE inhibits Mechanistic
PROCAINAMIDE HYDROCHLORIDE inhibits Mechanistic
PROPAFENONE HYDROCHLORIDE inhibits Mechanistic
LIDOCAINE HYDROCHLORIDE inhibits Mechanistic
QUINIDINE GLUCONATE inhibits Mechanistic
PRILOCAINE inhibits Mechanistic
ETHOTOIN inhibits Mechanistic
PF-05089771 inhibits Mechanistic
DICHLOROBENZYL ALCOHOL inhibits Mechanistic
RANOLAZINE ? unclear Mechanistic
PRILOCAINE HYDROCHLORIDE inhibits Mechanistic
ORPHENADRINE HYDROCHLORIDE inhibits Mechanistic

Showing top 40 of 271 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic
BENZYL ISOTHIOCYANATE ? unclear Mechanistic
ACETAMINOPHEN activates Mechanistic
POLYGODIAL ? unclear Mechanistic
PROPOFOL ? unclear Mechanistic
SAF312 inhibits Mechanistic
GRC-15300 ? unclear Mechanistic
AZD1386 inhibits Mechanistic
TIVANISIRAN inhibits Mechanistic
MAVATREP inhibits Mechanistic
MR-1817 inhibits Mechanistic
FERRUGINENE B ? unclear Mechanistic
CAPSAICIN activates Mechanistic 19.95 nM (EC50)
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic
VOACANGINE ? unclear Mechanistic
RESINIFERATOXIN activates Mechanistic 23.1 nM (Ki)
DWP05195 inhibits Mechanistic
XEN-D0501 inhibits Mechanistic
PAC-14028 inhibits Mechanistic
SB-705498 inhibits Mechanistic
MASOPROCOL ? unclear Mechanistic
ALLYL ISOTHIOCYANATE ? unclear Mechanistic
NGD-8243 inhibits Mechanistic
GRC-6211 inhibits Mechanistic
RESERPINE ? unclear Mechanistic
NABIXIMOLS ? unclear Mechanistic
A425619 ? unclear Mechanistic
PHE377 inhibits Mechanistic
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic
WORTMANNIN ? unclear Mechanistic
JTS-653 inhibits Mechanistic
LEVODOPA ? unclear Mechanistic
AMG517 inhibits Mechanistic
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki)
ZUCAPSAICIN activates Mechanistic
INDOMETHACIN ? unclear Mechanistic
CHEMBL:CHEMBL191534 ? unclear Mechanistic
ABT-102 inhibits Mechanistic
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic

Showing top 40 of 160 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT07487987 Phase: NA Started: 2026-03-10

The aim of this study is to compare the effects of single-session motor imagery and motor control exercises on pain, pressure pain threshold, cervical proprioception, and motor imagery in individuals with chronic neck pain.

NCT07681687 Phase: NA Started: 2026-01-01

A randomized controlled trial to evaluate the effectiveness of Sensory Motor Control training combined with Muscle Energy Technique in reducing pain and improving function, cervical range of motion, proprioception, and kinesiophobia in individuals with chronic mechanical neck pain

NCT07681349 Phase: NA Started: 2020-08-21

The goal of this clinical trial is to determine whether acupuncture can improve neck pain and shoulder movement in people with chronic neck pain. Researchers will compare acupuncture with sham acupuncture (a procedure designed to resemble acupuncture without therapeutic effects) to determine whether...

NCT07617623 Phase: NA Started: 2026-06

Chronic non-specific neck pain is a common musculoskeletal condition affecting a large proportion of the population worldwide. It is characterized by persistent neck pain lasting more than three months without a specific underlying pathology. Many patients experience ongoing symptoms such as pain, r...

NCT06044649 Phase: NA Started: 2023-11-15

Chronic musculoskeletal pain (CP) is a major public health concern. Psychosocial treatments have been shown to be efficacious when compared to largely inert control conditions, but they are characterized by modest effects on primary outcomes. One strategy to boost efficacy is to increase our underst...

NCT07663617 Phase: NA Started: 2026-04-20

This study will be conducted to investigate the effect of mechanical traction on pain, disability, cervical range of motion, sleep quality and insomnia in patients with chronic neck pain. Forty four female patients with chronic neck pain will participate in this study. The patients will be diagnosed...

NCT07630142 Phase: NA Started: 2026-06-01

This study evaluates whether a single session of percussion therapy can reduce muscle tension and increase blood flow in the transverse cervical artery in individuals with neck pain. The investigators will evaluate muscle stiffness using ultrasound elastography, and assess blood flow in the transver...

NCT07639671 Phase: NA Started: 2024-09-15

This prospective single-center study aims to evaluate the clinical efficacy of fluoroscopy-guided cervical interlaminar epidural steroid injection (CIESI) in patients with unilateral, single-level cervical radiculopathy due to cervical disc herniation. Unlike previous studies that assessed neck and ...

NCT06980337 Phase: NA Started: 2025-06-01

The purpose of the clinical trial is to investigate the effect of the combined Kendall and scapulothoracic exercises program on mechanosensitivity of brachial plexus, cervical range of motion, neck functional ability, and craniovertebral angle in patients with chronic non-specific neck pain. we hav...

NCT07613463 Phase: NA Started: 2025-02-12

Mechanical neck pain (MNP) refers to aches and pains in the cervical spine and around the cervicothoracic junction that do not have a specific anatomical or physical source. Multiple non-invasive physiotherapy methods can be used for treating MNP including bowen therapy and myofascial release therap...

NCT07579182 Phase: PHASE1 Started: 2026-05-17

The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in wo...

NCT06591221 Phase: NA Started: 2024-07-07

This study is a pragmatic randomized controlled study that assessed 250 subjects complaining of chronic bothersome neck pain with mild discomfort in a 1:1 ratio: chuna maintenance therapy group (125 subjects, 1 time/2 weeks, total 20 weeks) and lifestyle management \& self-exercise group (125 subjec...

NCT07606729 Phase: NA Started: 2026-01-10

Non-specific chronic neck pain represents a major global health burden, affecting 30% to 50% of the general population. It is particularly prevalent among office workers, computer users, and women, with a notable rise in young adults aged 20 to 24. While acute episodes of neck pain may initially res...

NCT06750718 Phase: NA Started: 2025-07-01

The research aims to treat chronic non-specific neck pain using virtual reality (VR) technologies with sensory-motor training. Chronic neck pain is widespread and highly prevalent in Egyptian society due to many factors, such as sitting for long periods in front of a computer or smartphone, which le...

NCT07266610 Phase: NA Started: 2025-11-28

The present study aims to evaluate the effects of deep neck stabilizers retraining with pressure biofeedback on cervical range of motion, pain, and temporomandibular dysfunction in patients with chronic neck pain. Participants will receive biofeedback-assisted deep neck flexor retraining in one gro...


Agents Found By Disease-Level Search

Searched directly from “Neck Pain (Chronic)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 6-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.